{"id":"NCT02836249","sponsor":"Gilead Sciences","briefTitle":"Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)","officialTitle":"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-19","primaryCompletion":"2017-03-21","completion":"2023-08-31","firstPosted":"2016-07-18","resultsPosted":"2018-04-17","lastUpdate":"2024-10-15"},"enrollment":181,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HBV","Chronic HBV Infection"],"interventions":[{"type":"DRUG","name":"TAF","otherNames":["GS-7340","Vemlidy®"]},{"type":"DRUG","name":"TDF","otherNames":["Viread®"]},{"type":"DRUG","name":"TAF Placebo","otherNames":[]},{"type":"DRUG","name":"TDF Placebo","otherNames":[]}],"arms":[{"label":"Double-Blind TAF","type":"EXPERIMENTAL"},{"label":"Double-Blind TDF","type":"ACTIVE_COMPARATOR"},{"label":"Open-label TAF","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection in China.","primaryOutcome":{"measure":"Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"Double-Blind: TAF 25 mg","deltaMin":61,"sd":null},{"arm":"Double-Blind: TDF 300 mg","deltaMin":68.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":12},"locations":{"siteCount":25,"countries":["China"]},"refs":{"pmids":["34221918","38779514","37771546"],"seeAlso":["https://www.gileadclinicaltrials.com/study/?id=GS-US-320-0110%20(China)"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":123},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Covid-19","Hepatic steatosis","Urinary tract infection"]}}